Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857720 | 0.83 | TSHR (0.55) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL8315393 | 0.81 | TSHR (0.57) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL15866823 | 0.78 | OPRM1 (0.40) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL15863219 | 0.78 | SLC6A3 (0.58) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL26625368 | 0.78 | ALDH1A1 (0.52) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL15862653 | 0.78 | ALDH1A1 (0.40) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL9175401 | 0.78 | SLC6A3 (0.58) | TSHRHTTHSD17B10SLC6A3SLC6A4 | |
| SCHEMBL21899382 | 0.77 | SLC6A3 (0.42) | TSHRHTTSLC6A3SLC6A4DPP4 | |
| SCHEMBL3550695 | 0.77 | DPP4 (0.62) | SLC6A3SLC6A4DPP4SLC6A2 | |
| SCHEMBL8319137 | 0.77 | TSHR (0.53) | TSHRHTTHSD17B10SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| CN-101115731-A | Oxadiazole derivatives as DGAT inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | TSHR 1451/4885HTT 1370/4885HSD17B10 151/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | TSHR 1169/4885HTT 1275/4885HSD17B10 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.